BenzingaAugust 13, 2026 at 7:25 AM NY22 days ago
JP Morgan Maintains Overweight on CytomX Therapeutics, Lowers Price Target to $11
JP Morgan analyst Anupam Rama maintains CytomX Therapeutics (NASDAQ:CTMX) with a Overweight and lowers the price target from $12 to $11.
Read the Full Story at the Source
The summary here comes from the news provider; the rest of the article lives on the publisher's site — Benzinga
Companies in This Story
Related Stories
Verisk CargoNet Reports Persistent Labor Day Cargo Theft Exposure Across U.S. Freight Networks
Yahoo5 hours ago
Which dow jones stocks are moving on Friday?
ChartMill5 hours ago
Exploring the top movers within the S&P500 index during today's session.
ChartMill6 hours ago
CAT Has Left Its Peers Behind. Or Has It?
Yahoo6 hours ago
AbbVie vs. Pfizer: Which Healthcare Stock Is a Better Buy in 2026?
Yahoo6 hours ago